John L. Jones
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
John L. Jones has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Ana Palacio
From the Division of General Internal Medicine, Department of Medicine, Miller School of Medicine
1 shared publicationArash Harzand
The Division of Medicine, Miller School of Medicine
1 shared publicationJoshua Hare
From the Division of General Internal Medicine, Department of Medicine, Miller School of Medicine
1 shared publication- Justin T. Whitfield
Center for Hematologic Malignancies, Memorial Sloan-Kettering Cancer Center, New York, New York
1 shared publication - Leonardo Tamariz
University of Miami
1 shared publication Michelle D. Lambert
Medical Pharmacology and Physiology, University of Missouri, Columbia, MO, USA
1 shared publication
Latest Publications
- Open Access
- 1 February 2016
- Published by Elsevier in Biophysical Journal
- Vol. 110 (3) , 99a
The TRPV4 Ion Channel Alters Intracellular Calcium Transients in Cardiomyocytes of Aged Mice
- 1 February 2016
- Published by Elsevier in Biophysical Journal
- Vol. 110 (3) , 99a
Open AccessThe TRPV4 Ion Channel Alters Intracellular Calcium Transients in Cardiomyocytes of Aged Mice
- 27 January 2011
- Published by Wiley in Congestive Heart Failure
- Vol. 17 (1) , 25-30
Uric Acid as a Predictor of All-Cause Mortality in Heart Failure: A Meta-Analysis
Serum uric acid (SUA) is a product of xanthine oxidase (XO). Apoptosis and tissue hypoxia lead to increased purine catabolism, which, in turn, increases XO activity and subsequently SUA levels. The purpose of this study was to perform a meta-analysis to evaluate the evidence supporting SUA as a predictor of all-cause mortality in patients with heart failure (HF) and to determine the SUA cut-off for the increase in risk. A search of the MEDLINE database (1966 to March 2009) supplemented by manual searches of bibliographies of key relevant articles was performed. The authors selected all cohort studies in which SUA was measured and mortality was reported in patients with HF. The pooled relative risk (RR) with the corresponding 95% confidence interval (CI) for all-cause mortality using the fixed-effects method was calculated. The effects of SUA on all-cause mortality at different SUA cut-offs using meta-regression was evaluated. The search strategy yielded 358 studies, of which only 6 met our eligibility criteria. The studies, however, comprised 1456 evaluable patients with HF, with a median ejection fraction of 32% (range, 26%-40%). The RR of all-cause mortality was 2.13 (95% CI, 1.78-2.55) for SUA>6.5 mg/dL compared with 7 mg/dL are associated with higher all-cause mortality.
- 27 January 2011
- Published by Wiley in Congestive Heart Failure
- Vol. 17 (1) , 25-30
Uric Acid as a Predictor of All-Cause Mortality in Heart Failure: A Meta-Analysis
Serum uric acid (SUA) is a product of xanthine oxidase (XO). Apoptosis and tissue hypoxia lead to increased purine catabolism, which, in turn, increases XO activity and subsequently SUA levels. The purpose of this study was to perform a meta-analysis to evaluate the evidence supporting SUA as a predictor of all-cause mortality in patients with heart failure (HF) and to determine the SUA cut-off for the increase in risk. A search of the MEDLINE database (1966 to March 2009) supplemented by manual searches of bibliographies of key relevant articles was performed. The authors selected all cohort studies in which SUA was measured and mortality was reported in patients with HF. The pooled relative risk (RR) with the corresponding 95% confidence interval (CI) for all-cause mortality using the fixed-effects method was calculated. The effects of SUA on all-cause mortality at different SUA cut-offs using meta-regression was evaluated. The search strategy yielded 358 studies, of which only 6 met our eligibility criteria. The studies, however, comprised 1456 evaluable patients with HF, with a median ejection fraction of 32% (range, 26%-40%). The RR of all-cause mortality was 2.13 (95% CI, 1.78-2.55) for SUA>6.5 mg/dL compared with 7 mg/dL are associated with higher all-cause mortality.